1 min readResearchers Determine How a Major Tumour Suppressor Pathway Becomes Deactivated
Boston, MA — The Hippo pathway is an important biological tumour suppressor program that controls cell growth and organ size in humans. Cancer cells have been found to frequently deactivate Hippo signalling in order to achieve increased cell growth and become more aggressive. However, how the Hippo pathway becomes deregulated in human cancers is still poorly understood.
Researchers now have found a new regulator of Hippo signalling that offers novel insights into how this critical signalling pathway becomes turned off in cancer cells.
“We have discovered that the enzyme STK25, a serine/threonine kinase, is a regulator of the Hippo tumour suppressor pathway,” said corresponding author Dr. Neil J. Ganem, assistant professor of pharmacology and medicine, section of haematology and medical oncology, at Boston University School of Medicine (BUSM).
The researchers used a combination of experiments in both cell lines and experimental models to study how STK25 regulates Hippo signalling. They found Hippo signalling was significantly impaired when they removed STK25 in cell lines. They also found this to be the case in models in which STK25 was genetically deleted. By studying cancer genetics databases, they discovered STK25 is frequently deleted in a wide range of human cancers, suggesting that its loss can promote cancer formation.
According to the researchers, STK25 regulates Hippo signalling in a manner that is completely different from the other identified components of the Hippo pathway to date and represents a completely novel way by which a major tumour suppressor pathway may become activated.
“Understanding how the Hippo pathway becomes deregulated in human cancers has been challenging, which has made it difficult to target this signalling pathway for therapeutic benefit. We hope our study ultimately leads to a better understanding of Hippo signalling deregulation in human cancers, and thus help promote the development of anticancer therapeutic options that did not previously exist.”
Article adapted from a Boston University School of Medicine news release.
Publication: Identification of the kinase STK25 as an upstream activator of LATS signalling. Lim, S et al. Nature Communications (April 04, 2019): Click here to view.